false
0000822370
0000822370
2024-07-03
2024-07-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 3, 2024
Emmaus Life Sciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35527 |
|
87-0419387 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
21250 Hawthorne Boulevard, Suite 800, Torrance, CA |
|
90503 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code (310) 214-0065
(Former name or former address, if changed, since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
None |
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operation and Financial Condition.
On July 3, 2024, Emmaus Life
Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) issued a press
release announcing the results of operations and financial condition as of and for the year ended December 31, 2023, a copy of which is
included as Exhibit 99.1 to this Current Report and incorporated herein by reference.
The
information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in
such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
See the accompanying Index to Exhibits, which information
is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: July 3, 2024 |
Emmaus Life Sciences, Inc. |
|
|
|
|
By: |
/s/ YASUSHI NAGASAKI |
|
|
Name: |
Yasushi Nagasaki |
|
|
Title: |
Chief Financial Officer |
INDEX TO EXHIBITS
Exhibit Number |
|
Description |
99.1 |
|
July 3, 2024 Press Release |
104 |
|
Cover Page Interactive Date File (embedded within Inline XBRL document) |
3
Exhibit 99.1
Emmaus Life Sciences Reports 2023 Financial
Results
Torrance CA, July 3, 2024 - Emmaus Life Sciences,
Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported
on its financial condition and results of operations as of and for the year ended December 31, 2023.
Recent Highlights
“We are pleased to report that we were able
to increase annual net revenues in 2023 by nearly 61% as compared to 2022 on the strength of growth in sales in the MENA region, as well
as in the U.S. As a result of the increased net revenues and the elimination of spending unrelated to Endari sales, we were able to increase
income from operations by approximately $10 million to $3.5 million and to reduce our net loss by $6.9 million to $3.7 million,”
remarked Willis Lee, Chairman of the Board and Co-president of Emmaus. “We also achieved an important strategic objective in the
fourth quarter of the year by disposing of our equity interest in our former Japanese joint venture,” he added.
“The much-improved financial results
for 2023 accomplished under our new management were adversely affected by a slowdown in Endari sales in the fourth quarter due to a
shortage of finished goods inventory, which also has had a material, adverse impact on sales in Q1 2024 and to date in Q2,”
noted George Sekulich, Emmaus’s Co-President and Chief Commercial Officer. “We have now remedied the shortage and begun
fulfilling our order backlog, which stood at approximately $4.6 million as of May 24, 2024. We are also working with alternative
manufacturers to avoid similar shortages in the future,” he added.
Financial and Operating Results
Net Revenues. Net revenues for the year
were $29.6 million, the highest annual revenues to date, compared to $18.4 million in 2022. The increased net revenues were attributable
to substantially increased net revenues from sales in the Middle East North Africa (MENA) region, as well as increased U.S. sales compared
to 2022.
Operating Expenses. Total operating expenses
for the year were $24.7 million compared with $22.4 million in 2022. The increase was due primarily to increases of $1.7 million in general
and administrative expenses and, $1.1 million in selling expenses, partially offset by a $0.5 million decrease in research and development
expenses.
Income From Operations. Income from operations
for the year was $3.5 million compared to a loss from operations of $6.6 million in 2022. The increase resulted from higher net revenues,
partially offset by increased general and administrative expenses and selling expenses compared to 2022.
Other Expense. The company incurred other
expense of $7.3 million for the year compared to $4.0 million in 2022. The increase was due primarily to an increase of $2.4 million in
interest expenses, a decrease of $1.5 million in change in fair value of conversion feature derivative attributable to our notes payable
compared to 2022 and a $0.3 million increase in loss on debt extinguishment, partially offset by a $0.9 million reduced foreign exchange
loss.
Net Loss. For the year, the company realized
net loss of $3.7 million, or $0.07 per share based on approximately 53.1 million weighted average basic common shares, compared a net
loss of $10.6 million, or $0.21 per share based on approximately 49.4 million weighted average basic and diluted common shares in 2022.
The decrease in net loss was primarily attributable to the increase in income from operations, partially offset by the increase in other
expense.
Liquidity and Capital Resources. At December
31, 2023, the company had cash and cash equivalents of $2.5 million, compared with $2.0 million on December 31, 2022.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage
biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated
to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United
States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in
France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus’ application for marketing authorization is awaiting final
action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.
About Endari® (prescription
grade L-glutamine oral powder)
Endari®, Emmaus’ prescription
grade L-glutamine oral powder, was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for treating sickle cell disease
in adult and pediatric patients five years of age and older.
Indication
Endari® is indicated to reduce
the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Important Safety Information
The most common adverse reactions (incidence >10
percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation
included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
The safety and efficacy of Endari®
in pediatric patients with sickle cell disease younger than five years of age has not been established.
For more information, please see full Prescribing
Information of Endari® at: www.ENDARIrx.com/PI.
About Sickle Cell
Disease
There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more
globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an
estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.1 The genetic mutation responsible
for SCD causes an individual’s red blood cells to distort into a “C” or a sickle shape, reducing their ability to transport
oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together,
which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads
to physical symptoms of incapacitating pain, tissue and organ damage, and early death.2
Forward-looking Statements
This press release contains forward-looking statements
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements
regarding the trend in sales in the MENA region and in the U.S. These forward-looking statements are subject to numerous assumptions,
risks and uncertainties which change over time, including the company’s need to restructure or refinance its existing indebtedness
and raise additional funds from related-party loans, third-party loans or other financing to meet its current liabilities and fund its
business and operations and doubt about the company’s ability to continue as a going concern and other factors disclosed in the
company’s Annual Report on Form 10-K for the year ended December 31, 2023, and actual results may differ materially. Such forward-looking
statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.
Company Contact:
Emmaus Life Sciences, Inc.
Willis Lee
Chairman and Co-president
(310) 214-0065, Ext. 1130
wlee@emmauslifesciences.com
(Financial Tables Follow)
1 | Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and
Developmental Disabilities, Centers for Disease Control and Prevention, December 2020. |
2 | Source: Committee on Addressing
Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020. |
Emmaus Life Sciences, Inc.
Condensed Consolidated
Statement of Operations and Comprehensive Income Loss
(In thousands, except share and per share amounts)
| |
Years Ended December 31 | |
| |
2023 | | |
2022 | |
Revenues, Net | |
$ | 29,597 | | |
$ | 18,390 | |
Cost of Goods Sold | |
| 1,342 | | |
| 2,588 | |
Gross Profit | |
| 28,255 | | |
| 15,802 | |
Operating Expenses | |
| 24,715 | | |
| 22,388 | |
Income (Loss) from Operations | |
| 3,540 | | |
| (6,586 | ) |
Total Other Expense | |
| (7,332 | ) | |
| (3,979 | ) |
Net Loss | |
| (3,733 | ) | |
| (10,625 | ) |
Comprehensive Loss | |
| (1,274 | ) | |
| (12,989 | ) |
Net Loss per Share | |
$ | (0.07 | ) | |
$ | (0.21 | ) |
Weighted Average Common Shares Outstanding | |
| 53,105,388 | | |
| 49,439,867 | |
Emmaus Life Sciences, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
| |
As of December 31, | |
| |
2023 | | |
2022 | |
Assets | |
| | |
| |
Current Assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 2,547 | | |
$ | 2,021 | |
Accounts receivable, net | |
| 5,524 | | |
| 375 | |
Inventories, net | |
| 1,711 | | |
| 2,379 | |
Prepaid expenses and other current assets | |
| 1,727 | | |
| 1,514 | |
Total Current Assets | |
| 11,509 | | |
| 6,289 | |
Property and Equipment, net | |
| 59 | | |
| 75 | |
Equity method investment | |
| - | | |
| 18,828 | |
Right of use assets | |
| 2,337 | | |
| 2,799 | |
Investment in convertible bond | |
| 20,978 | | |
| 19,971 | |
Other Assets | |
| 296 | | |
| 263 | |
Total Assets | |
$ | 35,179 | | |
$ | 48,225 | |
| |
| | | |
| | |
Liabilities and Stockholders’ Deficit | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 17,725 | | |
$ | 13,549 | |
Conversion feature derivative, notes payable | |
| 451 | | |
| 3,248 | |
Notes payable, current portion | |
| 8,215 | | |
| 6,814 | |
Convertible notes payable, net of discount | |
| 16,383 | | |
| 14,655 | |
Other current liabilities | |
| 18,733 | | |
| 16,057 | |
Total Current Liabilities | |
| 61,507 | | |
| 54,323 | |
Notes payable, less current portion | |
| - | | |
| 380 | |
Other long-term liabilities | |
| 21,428 | | |
| 27,613 | |
Total Liabilities | |
| 82,935 | | |
| 82,316 | |
Stockholders’ Deficit | |
| (47,756 | ) | |
| (34,091 | ) |
Total Liabilities & Stockholders’ Deficit | |
$ | 35,179 | | |
$ | 48,225 | |
5
v3.24.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Strive 500 ETF (AMEX:STRV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Strive 500 ETF (AMEX:STRV)
Historical Stock Chart
From Aug 2023 to Aug 2024